A: Dr. Jawad Bashir practices at Mediclinic Dubai Mall Medical Centre Br Mediclinic Clinics Llc - Muhaysnah Shamal.

A: Patients frequently visit Dr. Jawad Bashir for Internal Medicine, Weight management to reverse cardio-metabolic risks like dyslipidaemia, hypertension, insulin resistance and other obesity related complications as non-alcoholic fatty liver disease, Hormonal imbalances during pregnancy including earlier detection of gestational diabetes by using continuous glucose monitoring devices. To see more reasons visit the doctor's profile on Practo.

A: Dr. Jawad Bashir has the following qualifications - MBBS.

A: Dr. Jawad Bashir has an overall experience of 7 years. View where has Dr. Jawad Bashir practiced in the past.

A: Dr Jawad Bashir is a British-trained consultant endocrinologist with CCTs in endocrinology, diabetes, and internal medicine, and brings vast clinical experience spanning over 16 years. He has worked as a consultant endocrinologist in several large healthcare facilities in Dubai, UAE. Prior to relocating to the UAE, he served as a consultant endocrinologist at Basildon University Hospital, UK, until March 2021. Dr Bashir has delivered state-of-the-art services in all the centres he has worked at and has managed a variety of complex endocrine disorders related to thyroid, adrenal, testosterone replacement, polycystic ovary syndrome, and diabetes complications. He is an expert in the use of the latest technologies such as Freestyle Libre sensors, DEXCOM continuous glucose monitors, and insulin pump therapy. He applies primary preventive strategies for prediabetes reversal, promoting a healthy lifestyle, weight management, and encouraging longevity. Dr Bashir has achieved notable recognition for his contributions to medical science and clinical practice. He was awarded first prize in quality improvement projects by the Royal College of Physicians (UK) for his work in developing diabetes services. He also received the runner-up prize for the Wales Best Trainee Award for his innovative design of a mobile app for diabetes and endocrine trainees’ induction. At King’s Dubai, he organized the first-ever King’s clinical update in diabetes, endocrine, and obesity in July 2022. During his time at Swansea Institute of Life Sciences (UK), Dr Bashir was a co-investigator in several principal trials in diabetes, contributing to the research that led to the approval of Semaglutide, now known as Ozempic and Wegovy.. View more details about the doctor on Practo.